CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: GlobeNewswire
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024. CytoDyn believes its prior MASH study demonstrated a statistically significant benefit of leronlimab at a dosing level of 350 mg. To clarify the optimal dosing and evaluate the potential for combination therapy, SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis. CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to ev
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 [Yahoo! Finance]Yahoo! Finance
- CytoDyn to Host Webcast to Provide Company UpdateGlobeNewswire
- May 2024 Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- May 2024 Letter to ShareholdersGlobeNewswire
CYDY
Sec Filings
- 6/28/24 - Form SC
- 6/28/24 - Form 8-K
- 6/20/24 - Form SC
- CYDY's page on the SEC website